New Business Models for Financing Translational Medicine: The NCATS Portfolio
In collaboration with the NIH’s National Center for Advancing Translational Sciences (NCATS), the MIT Laboratory for Financial Engineering hosted an all-day meeting at MIT on January 28, 2014 to explore new business structures for raising and deploying funding for biomedical research and drug development in a scalable and profitable manner.
The meeting brought together a small group of potential investors, financial analysts, foundation officers, and senior NCATS personnel, and provided an opportunity to explore various forms of collaboration between the private sector and NCATS. The primary objective was to propose and outline new business structures for supporting preclinical and translational science efforts within the specific context of the NCATS portfolio. Participants had the opportunity to learn more about the NIH’s newest center and about its success rates and selection methods, which may be helpful in developing better risk models for ultra early stage investments in biomedicine.
|10:00am – 10:10am||Welcome and Introductions
Andrew W. Lo
|10:10am – 10:30am||Overview of NCATS
|10:30am – 11:15am||The TRND and BrIDGs Programs
|11:15am – 12:00pm||Preliminary Analysis of the NCATS Portfolio
Nora Yang and MIT team
|12:00pm – 1:00pm||Lunch|
|1:00pm – 2:30pm||Panel 1: Potential Business Structures
Chris Austin, Doug Dachille, John Frishkopf, Tom Rutledge, Roger Stein, Tom Unger
|2:30pm – 3:00pm||Break|
|3:00pm – 4:30pm||Panel 2: Industry and Patient Perspectives
Jim Broderick, Louis DeGennaro, Ilan Ganot, Edward Jung, Pablo Legorreta, Terry McGuire
|4:30pm – 5:30pm||Wrap-Up and Action Items|